Connect with us

Business

Pharmaceutical Firms Scale Back UK Investments Amid Drug Pricing Disputes

Published

on

Multinational drugmakers are pausing or pulling back investments in the United Kingdom, citing concerns over uncompetitive drug pricing and strained relations with the government. The slowdown comes as Britain seeks to position itself as a hub for life sciences, a sector the government has long promoted as central to its post-Brexit economic strategy.

Eli Lilly, AstraZeneca, and Merck are among the companies that have recently scaled back or halted projects in the UK. Earlier this month, AstraZeneca suspended a planned £200 million expansion of its Cambridge research site, following the cancellation of a vaccine project in Liverpool. Merck, known in Europe as MSD, said it would relocate its London research operations to the United States. Meanwhile, Eli Lilly has paused its £279 million London Gateway Lab, saying it was awaiting “more clarity around the UK life sciences environment.”

The moves follow sharp criticism from Eli Lilly’s chief executive Dave Ricks, who last week told the Financial Times that Britain was “probably the worst country in Europe” for drug pricing. His remarks have further highlighted growing friction between the pharmaceutical industry and the government.

Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), urged ministers to act. “We have a long and proud history of researching and manufacturing medicines in this country,” he said. “This is why we urge the government to improve how this country values and attracts future life sciences manufacturing.”

The UK spends a smaller share of its health budget on medicines than most developed nations — around 9% compared with 14–20% elsewhere. Much of this is due to the NHS’s heavy use of generic drugs and the role of the National Institute for Health and Care Excellence (NICE), which determines whether branded medicines are cost-effective. In addition, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) caps NHS spending on branded medicines, requiring firms to pay back revenue when expenditure exceeds agreed limits. Companies argue the rebates have become unsustainable.

Adding to the pressure, new U.S. trade policies are reshaping the global market. President Donald Trump recently announced 100% tariffs on branded drug imports unless firms build plants in the U.S., alongside a “most favoured nation” pricing policy that could ripple across Europe. With the U.S. accounting for roughly 70% of global pharma profits, analysts say many companies are prioritising American operations over European ones.

Experts note that higher UK drug prices are not necessarily the solution. Irene Papanicolas, director at the Brown University School of Public Health, argued that if pharma firms retreat, “the bigger impact is on the economy and jobs” rather than patient access to medicines. Beth Woods, senior research fellow at the University of York, added: “Our research supports more stringent price regulation in the UK. More investment could fund screening programmes, hip replacements, or staffing increases.”

Analysts say that beyond pricing, the UK must strengthen its tax incentives, infrastructure, and research funding to remain attractive. Without decisive action, they warn, Britain risks losing ground in the global competition for pharmaceutical investment.

Business

Trump Highlights McDonald’s in Economic Message as Beef Prices Rise

Published

on

President Donald Trump used a speech at the McDonald’s Impact Summit on Monday to cast himself as a champion of affordability, even as beef prices continue to rise for U.S. consumers.

Trump praised McDonald’s as “one of the most successful companies in the history of the world” and thanked the fast-food chain for lowering prices. His remarks came amid data showing the average price of ground beef reached $6.32 per pound in September, up about 13 percent from a year earlier.

The president also referenced the Big Mac Index, a widely recognized, though informal, measure of inflation. According to the latest Economist reading, a U.S. Big Mac cost $6.01 in July, up from $5.69 a year earlier and $5.15 three years ago. The index compares Big Mac prices across countries to illustrate changes in purchasing power.

“I’m honoured to stand before you as the very first former McDonald’s fry cook ever to become president of the United States,” Trump told McDonald’s franchise representatives in Washington. He highlighted a brief stint working behind the counter, a reference used throughout his 2024 campaign.

Trump also recalled serving McDonald’s on the campaign trail from his private plane, Trump Force One, and said he once made Robert F. Kennedy Jr. try a meal at the chain. In addition, he mentioned tech industry figures, thanking Sundar Pichai and Sergey Brin for acknowledging his McDonald’s-themed campaign skit, which he described as receiving “more hits than anything in the history of Google.”

The president’s remarks tied the fast-food chain to his economic message, emphasizing support for small businesses and affordable dining options. “As president, I’m fighting every day to support small businesses like yours… we’re making tremendous progress,” Trump said, addressing the franchisees in attendance.

Despite Trump’s framing, household budgets continue to feel the impact of higher prices. While inflation has eased somewhat since post-pandemic peaks, many consumers still pay more for everyday goods such as beef and coffee than in previous years. The U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers (CPI-U) rose 0.3 percent in September after increasing 0.4 percent in August.

Trump’s use of McDonald’s in his speech underscores the chain’s symbolic role as an American institution and a gauge of everyday affordability. By linking his message to the familiar restaurant brand, the president sought to present himself as closely connected to working-class concerns while highlighting ongoing economic initiatives.

Continue Reading

Business

Japan’s Economy Contracts as U.S. Tariffs Hit Exports, Posing Early Test for New Prime Minister

Published

on

Japan’s economy recorded a sharp slowdown in the July–September quarter, contracting for the first time in a year and a half as U.S. trade tariffs weighed heavily on exports. Government figures released on Monday showed an annualised decline of 1.8%, driven largely by weakened overseas demand after Washington imposed new duties on Japanese goods.

While the downturn was significant, it was not as steep as the 2.6% drop projected by economists. On a quarter-to-quarter basis, gross domestic product slipped 0.4%, ending six straight quarters of expansion and signalling a tougher economic landscape for recently appointed Prime Minister Sanae Takaichi.

Exports recorded one of the sharpest declines of the quarter, falling 1.2% from the previous period. The government noted that some firms rushed shipments earlier in the year to get ahead of tariff deadlines, which boosted earlier export data but resulted in weaker numbers for the autumn quarter. On an annualised basis, exports tumbled 4.5%.

Imports were slightly lower as well, dipping 0.1%, while private consumption — a key driver of the domestic economy — inched up by the same margin. Economists say the modest rise in household spending is not enough to offset the strain placed on the country’s major industries.

The tariff pressures stem from measures introduced by U.S. President Donald Trump, who has implemented a 15% duty on nearly all Japanese imports. Although this marks a reduction from the previous 25% rate, the impact has been severe for Japan’s export-heavy economy. Automakers such as Toyota Motor Corp. have long been central to Japan’s global trade profile, though many have built factories abroad to reduce exposure to such trade barriers.

The latest GDP results add to the mounting challenges facing Takaichi, who assumed office in October. Alongside the economic risks, her government is navigating rising diplomatic tensions with China. Earlier this month, the prime minister stated that Japan may consider military action if Beijing launches an attack on Taiwan, prompting sharp reactions from Chinese officials.

Talks between diplomats from both countries are scheduled to take place on Tuesday, with economic stability and regional security expected to dominate the agenda.

The combination of trade pressures, geopolitical strain and a fragile domestic recovery places Japan at a sensitive moment, with policymakers now under heightened pressure to stabilise growth in the months ahead.

Continue Reading

Business

Global Stocks Fall as Tech Valuations and Fed Rate Uncertainty Weigh on Markets

Published

on

Global equities declined on Friday as investors grew cautious over high valuations in technology and AI sectors, coupled with uncertainty about whether the US Federal Reserve will deliver further interest-rate cuts. European markets opened sharply lower following losses in Asian shares and a drop on Wall Street on Thursday.

“Markets are down across the board as investors fret about cracks in the narrative that’s driven the mother of all tech rallies over the past few years,” said Dan Coatsworth, head of markets at AJ Bell. He highlighted concerns over elevated equity prices and heavy spending on AI amid signs of a fragile labor market.

In Europe, UK government bond yields surged after reports that Chancellor Rachel Reeves had abandoned plans to raise income taxes in this month’s Autumn Budget, raising questions about a potential fiscal shortfall. The ten-year gilt yield climbed above 4.54% before easing slightly. Bank shares were among the worst performers on the FTSE 100, which fell more than 1.1% by 11:00 CET. Other European indices also declined, with the Stoxx 600 down nearly 1%, Germany’s DAX off 0.7%, France’s CAC 40 down 0.7%, Madrid’s benchmark losing 1.2% and Milan’s index down 1%.

Some companies bucked the overall trend. Luxury group Richemont rose 7.5% after exceeding first-half profit expectations, and Siemens Energy gained more than 10% after raising its 2028 financial targets. In contrast, Ubisoft delayed its six-month financial report, triggering a suspension in trading after an earlier drop of over 8%.

Wall Street had suffered a sharp decline on Thursday, with the S&P 500 and the Dow Jones Industrial Average both down 1.7%, and the Nasdaq falling 2.3%. Technology and AI-linked stocks experienced heavy selling, with Nvidia down 3.6%, Super Micro Computer off 7.4%, Palantir down 6.5%, Broadcom losing 4.3%, and Oracle sliding more than 4%. The sector’s rapid gains this year have drawn comparisons with the dot-com boom, prompting questions about the sustainability of current valuations.

Asian markets also reflected the cautious mood. China reported factory output growth at 4.9% year-on-year in October, the slowest in 14 months and below expectations. Weakness in fixed-asset investment, especially in the property sector, added to concerns. South Korea’s Kospi fell 3.8%, with Samsung Electronics down 5.5% and SK Hynix off 8.5%. Taiwan’s Taiex dropped 1.8%, Japan’s Nikkei 225 lost nearly 1.8%, and Hong Kong’s Hang Seng slipped 2%. The Shanghai Composite declined 1%.

Oil prices rose, with Brent crude up 1.6% at $63.99 per barrel and West Texas Intermediate climbing 1.8% to $59.76. The dollar strengthened slightly against the yen at ¥154.55, while the euro traded at $1.1637.

Investors continue to weigh the risks of stretched valuations in technology against uncertain monetary policy, leaving markets cautious as they head into the final months of 2025.

Continue Reading

Trending